Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 207

1.

Heterogeneity of Treatment Effects of Long-Acting Injectable Antipsychotic Medications.

Stroup TS, Bareis NA, Rosenheck RA, Swartz MS, McEvoy JP.

J Clin Psychiatry. 2018 Nov 27;80(1). pii: 18m12109. doi: 10.4088/JCP.18m12109.

PMID:
30549494
2.

Ingestion of plastic by fish: A comparison of Thames Estuary and Firth of Clyde populations.

McGoran AR, Cowie PR, Clark PF, McEvoy JP, Morritt D.

Mar Pollut Bull. 2018 Dec;137:12-23. doi: 10.1016/j.marpolbul.2018.09.054. Epub 2018 Oct 4.

PMID:
30503418
3.

Adjunct Aripiprazole Reduces Prolactin and Prolactin-Related Adverse Effects in Premenopausal Women With Psychosis: Results From the DAAMSEL Clinical Trial.

Kelly DL, Powell MM, Wehring HJ, Sayer MA, Kearns AM, Hackman AL, Buchanan RW, Nichols RB, Adams HA, Richardson CM, Vyas G, McMahon RP, Earl AK, Sullivan KM, Liu F, Luttrell SE, Dickerson FB, Feldman SM, Narang S, Koola MM, Buckley PF, RachBeisel JA, McEvoy JP.

J Clin Psychopharmacol. 2018 Aug;38(4):317-326. doi: 10.1097/JCP.0000000000000898.

PMID:
29912799
4.

What You Should Know About Tardive Dyskinesia: Screening, Causes, and New Treatment Options.

Manning JS, McEvoy JP.

J Clin Psychiatry. 2018 Jan/Feb;79(1). pii: NU16048WC3C. doi: 10.4088/JCP.NU16048WC3C.

5.

Evidence-Based Strategies for Managing Tardive Dyskinesia.

McEvoy JP.

J Clin Psychiatry. 2018 Jan/Feb;79(1). pii: NU16048CC2C. doi: 10.4088/JCP.NU16048CC2C.

6.

Durability of Therapeutic Response With Long-Term Aripiprazole Lauroxil Treatment Following Successful Resolution of an Acute Episode of Schizophrenia.

McEvoy JP, Risinger R, Mykhnyak S, Du Y, Liu CC, Stanford AD, Weiden PJ.

J Clin Psychiatry. 2017 Sep/Oct;78(8):1103-1109. doi: 10.4088/JCP.17m11625.

7.
8.

Inflammation, substance use, psychopathology, and cognition in phase 1 of the clinical antipsychotic trials of intervention effectiveness study.

Miller BJ, Buckley PF, McEvoy JP.

Schizophr Res. 2018 May;195:275-282. doi: 10.1016/j.schres.2017.08.027. Epub 2017 Aug 24.

PMID:
28843438
9.

Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.

Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isojärvi J, Jarskog LF, Jimenez-Shahed J, Kumar R, McEvoy JP, Ochudlo S, Ondo WG, Fernandez HH.

Lancet Psychiatry. 2017 Aug;4(8):595-604. doi: 10.1016/S2215-0366(17)30236-5. Epub 2017 Jun 28.

PMID:
28668671
10.

Adjunctive Minocycline in Clozapine-Treated Patients with Schizophrenia: Analyzing the Effects of Minocycline on Clozapine Plasma Levels.

Wehring HJ, Elsobky T, McEvoy JP, Vyas G, Richardson CM, McMahon RP, DiPaula BA, Liu F, Sullivan K, Buchanan RW, Feldman S, McMahon EM, Kelly DL.

Psychiatr Q. 2018 Mar;89(1):73-80. doi: 10.1007/s11126-017-9515-x.

PMID:
28466366
11.

Guide to the Management of Clozapine-Related Tolerability and Safety Concerns.

Citrome L, McEvoy JP, Saklad SR.

Clin Schizophr Relat Psychoses. Fall 2016;10(3):163-177. Review.

PMID:
27732102
12.

Placebo controls in clinical trials: concerns about use in relapse prevention studies in schizophrenia.

Emsley R, Fleischhacker WW, Galderisi S, Halpern LJ, McEvoy JP, Schooler NR.

BMJ. 2016 Sep 9;354:i4728. doi: 10.1136/bmj.i4728. No abstract available.

PMID:
27613560
13.

A Guide to the Management of Clozapine-Related Tolerability and Safety Concerns.

Citrome L, McEvoy JP, Saklad SR.

Clin Schizophr Relat Psychoses. 2016 Jul 25. [Epub ahead of print]

PMID:
27454214
14.

Use of Clozapine in Schizophrenia.

McEvoy JP.

JAMA Psychiatry. 2016 Oct 1;73(10):1097-1098. doi: 10.1001/jamapsychiatry.2016.1241. No abstract available.

PMID:
27438689
15.

The RAISE Connection Program: Psychopharmacological Treatment of People With a First Episode of Schizophrenia.

Kreyenbuhl JA, Medoff DR, McEvoy JP, Smith TE, Hackman AL, Nossel IR, Dixon LB, Essock SM, Buchanan RW.

Psychiatr Serv. 2016 Dec 1;67(12):1300-1306. Epub 2016 Jul 1.

16.

Prioritizing Harm.

Moyer KH, McEvoy JP, Mabe PA, Buchanan E, Venkatesan A, Buckley PF.

J Pers Assess. 2017 Jan-Feb;99(1):78-82. doi: 10.1080/00223891.2016.1180625. Epub 2016 Jun 1.

PMID:
27248047
17.

Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia.

Rosenheck RA, Leslie DL, Sint KJ, Lin H, Li Y, McEvoy JP, Byerly MJ, Hamer RM, Swartz MS, Stroup TS.

Psychiatr Serv. 2016 Oct 1;67(10):1124-1130. Epub 2016 Jun 1.

18.
19.

Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms.

Kelly DL, Sullivan KM, McEvoy JP, McMahon RP, Wehring HJ, Gold JM, Liu F, Warfel D, Vyas G, Richardson CM, Fischer BA, Keller WR, Koola MM, Feldman SM, Russ JC, Keefe RS, Osing J, Hubzin L, August S, Walker TM, Buchanan RW.

J Clin Psychopharmacol. 2015 Aug;35(4):374-81. doi: 10.1097/JCP.0000000000000345.

20.

Seizure control by derivatives of medium chain fatty acids associated with the ketogenic diet show novel branching-point structure for enhanced potency.

Chang P, Zuckermann AM, Williams S, Close AJ, Cano-Jaimez M, McEvoy JP, Spencer J, Walker MC, Williams RS.

J Pharmacol Exp Ther. 2015 Jan;352(1):43-52. doi: 10.1124/jpet.114.218768. Epub 2014 Oct 17.

21.

Antipsychotic medications for schizophrenia--reply.

Stroup TS, McEvoy JP, Hamer RM.

JAMA. 2014 Oct 8;312(14):1469. doi: 10.1001/jama.2014.10112. No abstract available.

PMID:
25291588
22.

Effectiveness of paliperidone palmitate vs haloperidol decanoate for maintenance treatment of schizophrenia: a randomized clinical trial.

McEvoy JP, Byerly M, Hamer RM, Dominik R, Swartz MS, Rosenheck RA, Ray N, Lamberti JS, Buckley PF, Wilkins TM, Stroup TS.

JAMA. 2014 May 21;311(19):1978-87. doi: 10.1001/jama.2014.4310. Erratum in: JAMA. 2014 Oct 8;312(14):1473.

23.

Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study.

Citrome L, Weiden PJ, McEvoy JP, Correll CU, Cucchiaro J, Hsu J, Loebel A.

CNS Spectr. 2014 Aug;19(4):330-9. doi: 10.1017/S109285291300093X. Epub 2013 Dec 16.

24.

High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study.

Goff DC, McEvoy JP, Citrome L, Mech AW, Bustillo JR, Gil R, Buckley P, Manschreck TC, Achtyes ED, Macklin EA.

J Clin Psychopharmacol. 2013 Aug;33(4):485-90. doi: 10.1097/JCP.0b013e3182977308.

PMID:
23775057
25.

Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study.

McEvoy JP, Citrome L, Hernandez D, Cucchiaro J, Hsu J, Pikalov A, Loebel A.

J Clin Psychiatry. 2013 Feb;74(2):170-9. doi: 10.4088/JCP.12m07992.

26.

Effects of switching from olanzapine, quetiapine, and risperidone to aripiprazole on 10-year coronary heart disease risk and metabolic syndrome status: results from a randomized controlled trial.

Stroup TS, Byerly MJ, Nasrallah HA, Ray N, Khan AY, Lamberti JS, Glick ID, Steinbook RM, McEvoy JP, Hamer RM.

Schizophr Res. 2013 May;146(1-3):190-5. doi: 10.1016/j.schres.2013.01.013. Epub 2013 Feb 21.

27.

Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia.

Jarskog LF, Dong Z, Kangarlu A, Colibazzi T, Girgis RR, Kegeles LS, Barch DM, Buchanan RW, Csernansky JG, Goff DC, Harms MP, Javitt DC, Keefe RS, McEvoy JP, McMahon RP, Marder SR, Peterson BS, Lieberman JA.

Neuropsychopharmacology. 2013 Jun;38(7):1245-52. doi: 10.1038/npp.2013.23. Epub 2013 Jan 16.

28.

Religious coping and quality of life among individuals living with schizophrenia.

Nolan JA, McEvoy JP, Koenig HG, Hooten EG, Whetten K, Pieper CF.

Psychiatr Serv. 2012 Oct;63(10):1051-4. doi: 10.1176/appi.ps.201000208.

29.

Optimizing outcome with antipsychotic treatment in first-episode schizophrenia: balancing efficacy and side effects.

Freudenreich O, McEvoy JP.

Clin Schizophr Relat Psychoses. 2012 Oct;6(3):115-21. Review.

PMID:
23006236
30.

Persistent infection with neurotropic herpes viruses and cognitive impairment.

Watson AM, Prasad KM, Klei L, Wood JA, Yolken RH, Gur RC, Bradford LD, Calkins ME, Richard J, Edwards N, Savage RM, Allen TB, Kwentus J, McEvoy JP, Santos AB, Wiener HW, Go RC, Perry RT, Nasrallah HA, Gur RE, Devlin B, Nimgaonkar VL.

Psychol Med. 2013 May;43(5):1023-31. doi: 10.1017/S003329171200195X. Epub 2012 Sep 14.

PMID:
22975221
31.

Evaluation of HLA polymorphisms in relation to schizophrenia risk and infectious exposure.

Bamne M, Wood J, Chowdari K, Watson AM, Celik C, Mansour H, Klei L, Gur RC, Bradford LD, Calkins ME, Santos AB, Edwards N, Kwentus J, McEvoy JP, Allen TB, Savage RM, Nasrallah HA, Gur RE, Perry RT, Go RC, Devlin B, Yolken R, Nimgaonkar VL.

Schizophr Bull. 2012 Nov;38(6):1149-54. doi: 10.1093/schbul/sbs087. Epub 2012 Sep 10.

32.

Exome sequencing followed by large-scale genotyping suggests a limited role for moderately rare risk factors of strong effect in schizophrenia.

Need AC, McEvoy JP, Gennarelli M, Heinzen EL, Ge D, Maia JM, Shianna KV, He M, Cirulli ET, Gumbs CE, Zhao Q, Campbell CR, Hong L, Rosenquist P, Putkonen A, Hallikainen T, Repo-Tiihonen E, Tiihonen J, Levy DL, Meltzer HY, Goldstein DB.

Am J Hum Genet. 2012 Aug 10;91(2):303-12. doi: 10.1016/j.ajhg.2012.06.018. Epub 2012 Aug 2.

33.

Heritability of functioning in families with schizophrenia in relation to neurocognition.

Savage RM, Wiener HW, Nimgaonkar V, Devlin B, Calkins ME, Gur RE, O'Jile J, Bradford LD, Edwards N, Kwentus J, Allen T, McEvoy JP, Nasrallah H, Santos AB, Aduroja T, Lahti A, May RS, Montgomery-Barefield L, Go RC.

Schizophr Res. 2012 Aug;139(1-3):105-9. doi: 10.1016/j.schres.2012.04.015. Epub 2012 May 23.

PMID:
22627125
34.

Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial.

Covell NH, McEvoy JP, Schooler NR, Stroup TS, Jackson CT, Rojas IA, Essock SM; Schizophrenia Trials Network.

J Clin Psychiatry. 2012 May;73(5):669-75. doi: 10.4088/JCP.11m07074. Epub 2012 Mar 6.

35.

Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia.

Javitt DC, Buchanan RW, Keefe RS, Kern R, McMahon RP, Green MF, Lieberman J, Goff DC, Csernansky JG, McEvoy JP, Jarskog F, Seidman LJ, Gold JM, Kimhy D, Nolan KS, Barch DS, Ball MP, Robinson J, Marder SR.

Schizophr Res. 2012 Apr;136(1-3):25-31. doi: 10.1016/j.schres.2011.11.001. Epub 2011 Dec 12.

PMID:
22169248
36.

Substance use and schizophrenia: adverse correlates in the CATIE study sample.

Kerfoot KE, Rosenheck RA, Petrakis IL, Swartz MS, Keefe RS, McEvoy JP, Stroup TS; CATIE Investigators.

Schizophr Res. 2011 Nov;132(2-3):177-82. doi: 10.1016/j.schres.2011.07.032. Epub 2011 Aug 26.

PMID:
21872443
37.

A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP).

Stroup TS, McEvoy JP, Ring KD, Hamer RH, LaVange LM, Swartz MS, Rosenheck RA, Perkins DO, Nussbaum AM, Lieberman JA; Schizophrenia Trials Network.

Am J Psychiatry. 2011 Sep;168(9):947-56. doi: 10.1176/appi.ajp.2011.10111609. Epub 2011 Jul 18.

38.

Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE study.

Stroup TS, Appelbaum PS, Gu H, Hays S, Swartz MS, Keefe RS, Kim SY, Manschreck TC, Boshes RA, McEvoy JP, Lieberman JA.

Schizophr Res. 2011 Aug;130(1-3):47-52. doi: 10.1016/j.schres.2011.04.012. Epub 2011 May 10.

39.

Effectiveness of switching from antipsychotic polypharmacy to monotherapy.

Essock SM, Schooler NR, Stroup TS, McEvoy JP, Rojas I, Jackson C, Covell NH; Schizophrenia Trials Network.

Am J Psychiatry. 2011 Jul;168(7):702-8. doi: 10.1176/appi.ajp.2011.10060908. Epub 2011 May 2.

40.

Review: clozapine shows some improved clinical efficacy over risperidone and zotepine in treatment of schizophrenia, but robust evidence is lacking.

McEvoy JP, Freudenreich O.

Evid Based Ment Health. 2011 May;14(2):53. doi: 10.1136/ebmh.14.2.53. No abstract available.

PMID:
21502159
41.

A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia.

Buchanan RW, Keefe RS, Lieberman JA, Barch DM, Csernansky JG, Goff DC, Gold JM, Green MF, Jarskog LF, Javitt DC, Kimhy D, Kraus MS, McEvoy JP, Mesholam-Gately RI, Seidman LJ, Ball MP, McMahon RP, Kern RS, Robinson J, Marder SR.

Biol Psychiatry. 2011 Mar 1;69(5):442-9. doi: 10.1016/j.biopsych.2010.09.052. Epub 2010 Dec 8.

42.

Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia.

McClay JL, Adkins DE, Aberg K, Bukszár J, Khachane AN, Keefe RS, Perkins DO, McEvoy JP, Stroup TS, Vann RE, Beardsley PM, Lieberman JA, Sullivan PF, van den Oord EJ.

Neuropsychopharmacology. 2011 Feb;36(3):616-26. doi: 10.1038/npp.2010.193. Epub 2010 Nov 24.

43.

Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia.

Addington DE, Mohamed S, Rosenheck RA, Davis SM, Stroup TS, McEvoy JP, Swartz MS, Lieberman JA.

J Clin Psychiatry. 2011 Jan;72(1):75-80. doi: 10.4088/JCP.09m05258gre. Epub 2010 Sep 21.

44.

Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.

Caroff SN, Davis VG, Miller DD, Davis SM, Rosenheck RA, McEvoy JP, Campbell EC, Saltz BL, Riggio S, Chakos MH, Swartz MS, Keefe RS, Stroup TS, Lieberman JA; CATIE Investigators.

J Clin Psychiatry. 2011 Mar;72(3):295-303. doi: 10.4088/JCP.09m05793yel. Epub 2010 Aug 10.

45.

A justice system that denies free will is not based on justice.

McEvoy JP.

Proc Natl Acad Sci U S A. 2010 May 18;107(20):E81; author reply E82. doi: 10.1073/pnas.1003504107. Epub 2010 May 7. No abstract available.

46.

First- and second-generation antipsychotics.

McEvoy JP, Zigman D, Margolese HC.

Can J Psychiatry. 2010 Mar;55(3):144-8; discussion 148-9. No abstract available.

PMID:
20370964
47.

Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs.

Adkins DE, Aberg K, McClay JL, Bukszár J, Zhao Z, Jia P, Stroup TS, Perkins D, McEvoy JP, Lieberman JA, Sullivan PF, van den Oord EJ.

Mol Psychiatry. 2011 Mar;16(3):321-32. doi: 10.1038/mp.2010.14. Epub 2010 Mar 2.

48.

Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study.

Meyer JM, McEvoy JP, Davis VG, Goff DC, Nasrallah HA, Davis SM, Hsiao JK, Swartz MS, Stroup TS, Lieberman JA.

Biol Psychiatry. 2009 Dec 1;66(11):1013-22. doi: 10.1016/j.biopsych.2009.06.005. Epub 2009 Jul 29.

49.

Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study.

Patel JK, Buckley PF, Woolson S, Hamer RM, McEvoy JP, Perkins DO, Lieberman JA; CAFE Investigators.

Schizophr Res. 2009 Jun;111(1-3):9-16. doi: 10.1016/j.schres.2009.03.025. Epub 2009 Apr 26.

PMID:
19398192
50.

Much ado about small differences.

McEvoy JP.

World Psychiatry. 2009 Feb;8(1):29-30. No abstract available.

Supplemental Content

Loading ...
Support Center